Headsafe sets up U.S. parent to push Nurochek concussion device

Headsafe has formed Headsafe Holdings, Inc. as its U.S. parent company, putting the Delaware-incorporated entity at the center of its commercial push for the FDA-cleared Nurochek portable EEG system. The move is aimed at accelerating adoption in emergency care, neurology and sports medicine, where clinicians need faster, more objective concussion assessments.

Why it matters: - Headsafe is betting the U.S. will be the main engine for commercial growth of Nurochek, its FDA-cleared concussion assessment device. - The new corporate structure is meant to give hospitals, clinics and distribution partners a U.S.-based company behind the product. - Faster, more objective concussion assessment can affect decisions in emergency departments, urgent care, neurology clinics and sports programs.

What happened: - Headsafe announced Headsafe Holdings, Inc. as the new Delaware-incorporated U.S. parent company for the Headsafe Group. - The company said the U.S. is now its primary growth market. - Headsafe said the new parent company gives it a platform to expand global commercialization of Nurochek, the portable EEG device used as an aid to concussion diagnosis. - Chief Executive Officer Craig Corrance said the U.S. offers a strong platform to build commercial presence, strengthen clinical partnerships and accelerate adoption.

The details: - Nurochek uses electroencephalography and visual evoked potentials to measure how the brain responds to controlled visual stimuli. - A trained healthcare professional fits a lightweight headset, then guided software runs the assessment. - Built-in artificial intelligence and machine learning analyze the signal and produce an objective report for the clinician. - The test takes about two minutes and does not require a baseline test. - Nurochek does not replace CT or MRI when structural injury is a concern. - Nurochek does not replace clinical judgment. - Nurochek adds objective brain function data to the standard neurological assessment. - Headsafe entered the U.S. market in January 2026 with the launch of Nurochek. - Headsafe appointed Corrance, a veteran MedTech executive, to lead the company. - Headsafe has built a U.S. distribution network that includes partnerships with Spartan Medical and 4U Solutions, among others. - The company said it continues to add distribution partners as adoption expands. - Adoption efforts are centered on emergency medicine, urgent care, neurology, sports medicine and certified athletic trainers.

Between the lines: - The move signals a shift from product development to commercial execution. - Headsafe is trying to match how healthcare buyers think about long-term support, service and clinical integration. - The company is positioning Nurochek as a workflow tool for high-volume concussion settings, not a replacement for imaging or clinical evaluation. - The U.S. parent company may also make the company look more durable to institutions that prefer domestic commercial partners.

What's next: - Headsafe said it will keep expanding clinical partnerships and distribution as it pushes adoption. - Clinicians, healthcare organizations and distribution partners can request information at more information or by emailing info@headsafe.com. - Product brochure, images and additional materials are available on request. - Headsafe is focused on implementation, training and clinical workflow integration as it scales in the U.S. and abroad.

The bottom line: - Headsafe is turning its U.S. business into the company’s commercial base as it works to make Nurochek a standard tool for concussion assessment.